These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 6239145)
1. [LHRH analogs--new possibilities in the treatment of prostatic cancer]. Baranowska B Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145 [No Abstract] [Full Text] [Related]
2. [Zoladex in prostatic carcinoma]. Di Silverio F; Serio M Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501 [No Abstract] [Full Text] [Related]
3. [Treatment of carcinoma of the prostate with analogs of LHRH]. Rubio Herrera MA; Calle Fernández JR Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782 [No Abstract] [Full Text] [Related]
4. [Treatment of cancer of the prostate. Role of gonadorelin analogs]. Steg A Presse Med; 1989 May; 18(20):1007-9. PubMed ID: 2524792 [No Abstract] [Full Text] [Related]
5. [Treatment of advanced cancer of the prostate using LHRH analogs. How can a possible initial flare-up be prevented?]. Bouffioux C; Denis L; Mahler C; de Leval J Acta Urol Belg; 1986; 54(3):304-8. PubMed ID: 2946208 [No Abstract] [Full Text] [Related]
6. [Luteinizing hormone-releasing hormone agonists for treatment of breast cancer]. Gez E; Kovner F Harefuah; 1990 Jun; 118(11):655-8. PubMed ID: 2143745 [No Abstract] [Full Text] [Related]
7. [Gn-RH analogs and benign prostatic hypertrophy]. Forti G; Serio M Drugs Exp Clin Res; 1990; 16 Suppl():31-2. PubMed ID: 1706977 [No Abstract] [Full Text] [Related]
8. [Hormone therapy of male genital cancer (prostatic cancer)]. Machida T; Ikemoto I Gan To Kagaku Ryoho; 1987 Oct; 14(10):2845-52. PubMed ID: 2444164 [TBL] [Abstract][Full Text] [Related]
9. Treatment with different GnRH analogues in women: preliminary evidence for disparant effects on serum androgen concentrations. Rossmanith WG; Wirth U; Sasse V; Lauritzen C Horm Metab Res; 1991 Apr; 23(4):198-9. PubMed ID: 1831437 [No Abstract] [Full Text] [Related]
10. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment. Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851 [No Abstract] [Full Text] [Related]
11. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment. Wenderoth UK; Jacobi GH Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176 [TBL] [Abstract][Full Text] [Related]
13. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer. Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265 [No Abstract] [Full Text] [Related]
14. Endocrine factors in the treatment of prostatic cancer. Pierrepoint CG; Turkes AO; Walker KJ; Harper ME; Wilson DW; Peeling WB; Griffiths K Prog Clin Biol Res; 1985; 185A():51-72. PubMed ID: 3162177 [No Abstract] [Full Text] [Related]
15. Treatment with an LHRH analogue in patients with advanced pancreatic cancer. A preliminary report. Andrén-Sandberg A Acta Chir Scand; 1990 Aug; 156(8):549-51. PubMed ID: 2146849 [TBL] [Abstract][Full Text] [Related]